Hims & Hers Health Inc. (HIMS) experienced a significant surge of 5.61% over the 24-hour trading period, marking a notable upward movement for the telehealth company's stock.

The price action follows a period of high volatility. The stock had previously rallied over 50% in the prior week driven by significant regulatory developments. The FDA is considering removing several peptide drugs from its restriction list and has confirmed plans to convene an expert panel to discuss pharmacy compounding of certain peptide substances. These developments were seen as potentially easing regulatory pressure on the company's compounding and weight-loss business lines. The recent intraday activity, which included a pullback, suggests profit-taking as investors reassess positioning ahead of the formal FDA review timeline scheduled for July.

Competitive dynamics also influenced trading sentiment. Amazon's launch of a comprehensive weight management and GLP-1 drug program introduced new competitive pressure in the telehealth and pharmacy space, which initially weighed on the stock. However, analyst commentary provided a counterpoint, with Citi noting that Amazon's on-demand option is not a direct replacement for dedicated platforms like Hims & Hers, potentially mitigating concerns over market share erosion.